DYN: Dyne Therapeutics, Inc. - Summary | Jitta

Dyne Therapeutics, Inc.

NASDAQ:DYN

Price
$17.04
Loss Chance
58.9%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (17)
Financial Strength (36)
Return to Shareholders (0)
Competitive Advantage (1)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Cash Conversion CycleLess than 30 days
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.22
132.29%
3.06
159.05%
Biotechnology
5.68
37.56%
5.68
37.56%
6.36
42.83%
COMPANY DESCRIPTION
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.